Neurogene
NGNE
36 hedge funds and large institutions have $53.7M invested in Neurogene in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
36% more capital invested
Capital invested by funds: $39.3M → $53.7M (+$14.3M)
9% more funds holding
Funds holding: 33 → 36 (+3)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0.19% less ownership
Funds ownership: 3.54% → 3.35% (-0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.04M |
| 2 |
Millennium Management
New York
|
+$1.25M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.23M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$1.13M |
| 5 |
Renaissance Technologies
New York
|
+$869K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$367K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$296K |
| 3 |
EP
Eversept Partners
New York
|
-$174K |
| 4 |
JP Morgan Chase
New York
|
-$114K |
| 5 |
SIM
Spark Investment Management
New York
|
-$109K |
NGNE Hedge Fund Activity: Q3 2019 in Review
36 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2019, worth a combined $53.7M — up 36% from $39.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NGNE positions and 7 closed out — a net gain of 3 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $3.04M. The largest seller was Oxford Asset Management, cutting an estimated $367K.
- 36 institutional investors held Neurogene (NGNE) as of Q3 2019, up from 33 in Q2 2019.
- Funds reported $53.7M of Neurogene stock for Q3 2019, up 36% quarter-over-quarter.
- 10 funds opened new Neurogene positions in Q3 2019 and 7 closed out, a net change of +3 holders.
- The largest Neurogene buyer in Q3 2019 was Opaleye Management, an estimated $3.04M added.
- The largest Neurogene seller in Q3 2019 was Oxford Asset Management, an estimated $367K sold.
Based on aggregated 13F filings for Q3 2019.